SA520412473B1 - مركب أميد حلقي غير متجانس معالج بالنيتروجين واستخدامه لأغراض طبية - Google Patents

مركب أميد حلقي غير متجانس معالج بالنيتروجين واستخدامه لأغراض طبية Download PDF

Info

Publication number
SA520412473B1
SA520412473B1 SA520412473A SA520412473A SA520412473B1 SA 520412473 B1 SA520412473 B1 SA 520412473B1 SA 520412473 A SA520412473 A SA 520412473A SA 520412473 A SA520412473 A SA 520412473A SA 520412473 B1 SA520412473 B1 SA 520412473B1
Authority
SA
Saudi Arabia
Prior art keywords
compound
methyl
acid
mixture
mhz
Prior art date
Application number
SA520412473A
Other languages
Arabic (ar)
English (en)
Inventor
ياماوكا بوبوتاكا
مايبا تاكاكي
موتودا داي
ماسو ريتسوكي
سوزاوا كويتشي
كوتوكو ماسايوكي
Original Assignee
جابان توباكو انك
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by جابان توباكو انك filed Critical جابان توباكو انك
Publication of SA520412473B1 publication Critical patent/SA520412473B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/99—Enzyme inactivation by chemical treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
SA520412473A 2018-02-01 2020-07-21 مركب أميد حلقي غير متجانس معالج بالنيتروجين واستخدامه لأغراض طبية SA520412473B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2018016328 2018-02-01

Publications (1)

Publication Number Publication Date
SA520412473B1 true SA520412473B1 (ar) 2023-02-12

Family

ID=67479787

Family Applications (1)

Application Number Title Priority Date Filing Date
SA520412473A SA520412473B1 (ar) 2018-02-01 2020-07-21 مركب أميد حلقي غير متجانس معالج بالنيتروجين واستخدامه لأغراض طبية

Country Status (21)

Country Link
US (4) US10800784B2 (enExample)
EP (1) EP3747888A4 (enExample)
JP (3) JP7241556B2 (enExample)
KR (1) KR102725118B1 (enExample)
CN (1) CN111655692B (enExample)
AR (1) AR114237A1 (enExample)
AU (1) AU2019214048B2 (enExample)
BR (1) BR112020014177A2 (enExample)
CA (1) CA3090219A1 (enExample)
CL (1) CL2020002003A1 (enExample)
CO (1) CO2020009420A2 (enExample)
IL (1) IL276386B2 (enExample)
MX (1) MX2020008126A (enExample)
MY (1) MY205011A (enExample)
PE (1) PE20211273A1 (enExample)
PH (1) PH12020500613A1 (enExample)
SA (1) SA520412473B1 (enExample)
SG (1) SG11202006916SA (enExample)
TW (1) TWI803570B (enExample)
WO (1) WO2019151274A1 (enExample)
ZA (1) ZA202004548B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3851103A4 (en) 2018-09-11 2022-06-08 Japan Tobacco Inc. THERAPEUTIC OR PROPHYLACTIC AGENT FOR CHRONIC KIDNEY DISEASE CONTAINING A PYRAZOLE-AMIDE COMPOUND
WO2023032940A1 (ja) 2021-09-01 2023-03-09 日本たばこ産業株式会社 含窒素三環性化合物及びその医薬用途
CN110407744A (zh) * 2019-08-13 2019-11-05 上海毕得医药科技有限公司 一种1-(4-氨基吡啶-2-基)乙酮的合成方法
PT4097099T (pt) 2020-02-07 2024-07-19 Gasherbrum Bio Inc Agonistas heterocíclicos de glp-1
BR112022014749A2 (pt) * 2020-03-04 2022-10-11 Japan Tobacco Inc Composto tricíclico fundido e uso medicinal do mesmo
WO2022052958A1 (en) * 2020-09-10 2022-03-17 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
AU2022244941B2 (en) * 2021-03-23 2024-08-01 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Heterocycle substituted ketone derivative, and composition and medicinal use thereof
KR20250168210A (ko) 2023-02-16 2025-12-02 가셔브룸 바이오, 인크. 헤테로시클릭 glp-1 효능제

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7943617B2 (en) * 2006-11-27 2011-05-17 Bristol-Myers Squibb Company Heterobicyclic compounds useful as kinase inhibitors
WO2008132162A1 (en) * 2007-04-26 2008-11-06 Boehringer Ingelheim International Gmbh 3- (sulphonylamino) -phenyl-2 -hydroxy-ethylamino derivatives useful as beta-agonists, processes for preparing them and their use as medicaments
AU2008263206A1 (en) * 2007-06-01 2008-12-18 Schering Corporation Gamma secretase modulators
EP2090576A1 (en) * 2008-02-01 2009-08-19 Merz Pharma GmbH & Co.KGaA 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators
AR074797A1 (es) * 2008-10-10 2011-02-16 Japan Tobacco Inc Compuesto de fluoreno , composiciones farmaceuticas , inhibidores de pdhk y pdhk2 , metodos de tratamiento , usos de los mismos y kit comercial
MX364602B (es) * 2011-06-27 2019-05-02 Alectos Therapeutics Inc Inhibidores selectivos de glicosidasa y usos de los mismos.
CA2855009C (en) * 2011-11-15 2019-07-09 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds useful as gpr119 agonists
WO2013187646A1 (en) * 2012-06-12 2013-12-19 Chong Kun Dang Pharmaceutical Corp. Piperidine derivatives for gpr119 agonist
CN103570725B (zh) 2012-08-01 2017-03-22 中国科学院上海药物研究所 哌嗪并三唑类化合物及其制备方法和用途
TWI633885B (zh) * 2013-03-15 2018-09-01 日商日本煙草產業股份有限公司 吡唑-醯胺化合物及其醫藥用途
TW201536748A (zh) * 2013-07-01 2015-10-01 Japan Tobacco Inc 茀-醯胺化合物及其醫藥用途
WO2015002119A1 (ja) 2013-07-01 2015-01-08 日本たばこ産業株式会社 ピラゾール-アルコール化合物およびその医薬用途
GB201316823D0 (en) * 2013-09-23 2013-11-06 R & D Vernalis Ltd New Chemical Entities
CA2933927C (en) 2013-12-17 2021-11-16 Merck Patent Gmbh N1-(3,3,3-trifluoro-2-hydroxo-2-methylpropionyl)-piperidine derivatives as inhibitors of pyruvate dehydrogenase kinase
CA2994027C (en) 2015-07-31 2023-10-10 Merck Patent Gmbh Bicyclic heterocyclic derivatives
EP3436443B1 (en) 2016-03-29 2020-03-11 Merck Patent GmbH N1-(3,3,3-trifluoro-2-hydroxy-2-methylpropionyl)-piperidine derivatives as inhibitors of pyruvate dehydrogenase kinase
CN109071490B (zh) * 2016-04-28 2021-04-06 默克专利股份公司 哌啶基衍生物
EP3492452B1 (en) * 2016-07-29 2022-08-31 Japan Tobacco Inc. Production method for pyrazole-amide compound
US10414774B2 (en) 2016-08-15 2019-09-17 Merck Sharp & Dohme Corp. Compound useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolc disease
LT3532064T (lt) 2016-10-28 2020-09-25 H. Lundbeck A/S Kompleksiniai gydymai, apimantys imidazopirazonus, skirti psichiatrinių ir (arba) kognityvinių sutrikimų gydymui
RU2019108717A (ru) 2016-10-28 2020-11-30 Х. Лундбекк А/С Комбинированные средства для лечения, предусматривающего введение имидазопиразинонов
WO2023032940A1 (ja) * 2021-09-01 2023-03-09 日本たばこ産業株式会社 含窒素三環性化合物及びその医薬用途
BR112022014749A2 (pt) * 2020-03-04 2022-10-11 Japan Tobacco Inc Composto tricíclico fundido e uso medicinal do mesmo

Also Published As

Publication number Publication date
CL2020002003A1 (es) 2020-10-23
JP2023071925A (ja) 2023-05-23
JP2024116307A (ja) 2024-08-27
MX2020008126A (es) 2020-09-18
RU2020128593A (ru) 2022-03-03
WO2019151274A1 (ja) 2019-08-08
KR102725118B1 (ko) 2024-11-04
MY205011A (en) 2024-09-27
PH12020500613A1 (en) 2021-05-31
CA3090219A1 (en) 2019-08-08
US20260070910A1 (en) 2026-03-12
SG11202006916SA (en) 2020-08-28
PE20211273A1 (es) 2021-07-19
AU2019214048A1 (en) 2020-06-25
AR114237A1 (es) 2020-08-05
JP2019131544A (ja) 2019-08-08
CO2020009420A2 (es) 2020-08-10
CN111655692B (zh) 2023-10-10
US20200017505A1 (en) 2020-01-16
EP3747888A1 (en) 2020-12-09
US10800784B2 (en) 2020-10-13
JP7241556B2 (ja) 2023-03-17
US20210284644A1 (en) 2021-09-16
EP3747888A4 (en) 2021-12-15
TW201934553A (zh) 2019-09-01
US20240300952A1 (en) 2024-09-12
KR20200115566A (ko) 2020-10-07
CN111655692A (zh) 2020-09-11
IL276386B2 (en) 2023-06-01
ZA202004548B (en) 2021-10-27
IL276386A (en) 2020-09-30
AU2019214048B2 (en) 2023-03-16
BR112020014177A2 (pt) 2020-12-08
TWI803570B (zh) 2023-06-01

Similar Documents

Publication Publication Date Title
JP7033764B2 (ja) Cdk阻害剤としての置換型ヘテロシクリル誘導体
AU2016256728B2 (en) Thiadiazole analogs thereof and methods for treating smn-deficiency-related-conditions
JP2022071046A (ja) Wdr5タンパク質-タンパク質結合の阻害剤
JP7759877B2 (ja) 治療用化合物
AU2019214048B2 (en) Nitrogenated heterocyclic amide compound, and use thereof for medical purposes
WO2022199586A1 (zh) 嘧啶并吡啶类抑制剂及其制备方法和应用
JP7212763B2 (ja) KEAP1-Nrf2タンパク質-タンパク質相互作用の阻害剤
JP7200120B2 (ja) Mk2阻害剤として有用なヘテロアリール化合物
EA016301B1 (ru) Пирролопиримидины и их применение
WO2015074064A2 (en) Tetrahydroquinoline compositions as bet bromodomain inhibitors
KR20210095143A (ko) Hbv의 치료를 위한 5원 헤테로아릴 카르복스아미드 화합물
EP2976341A1 (en) Acyclic cyanoethylpyrazolo pyridones as janus kinase inhibitors
CN113045569B (zh) 用作ret激酶抑制剂的化合物及其应用
JP7447098B2 (ja) アミノピリミジン化合物
AU2022337617A1 (en) Nitrogen-containing tricyclic compound and pharmaceutical use thereof
RU2789670C2 (ru) Азотсодержащий гетероциклический амид и его применение для медицинских целей
JP7618898B1 (ja) ヒト呼吸器合胞体ウイルス及びメタニューモウイルスの阻害薬
JP6535007B2 (ja) 新規ピペリジンカルボキサミド化合物、その調製方法及び使用
US20250066356A1 (en) Lrrk2 inhibitors
HK40041663A (en) Nitrogenated heterocyclic amide compound, and use thereof for medical purposes